Skip header and navigation

2 records – page 1 of 1.

The Oslo Health Study: Is bone mineral density higher in affluent areas?

https://arctichealth.org/en/permalink/ahliterature84470
Source
Int J Equity Health. 2007 Nov 23;6(1):19
Publication Type
Article
Date
Nov-23-2007
Author
AlverKari
SogaardAnne
FalchJan
MeyerHaakon
Source
Int J Equity Health. 2007 Nov 23;6(1):19
Date
Nov-23-2007
Language
English
Publication Type
Article
Abstract
ABSTRACT: BACKGROUND: Based on previously reported differences in fracture incidence in the socioeconomic less affluent Oslo East compared to the more privileged West, our aim was to study bone mineral density (BMD) in the same socioeconomic areas in Oslo. We also wanted to study whether possible associations were explained by socio-demographic factors, level of education or lifestyle factors. METHODS: Distal forearm BMD was measured in random samples of the participants in The Oslo Health Study by single energy x-ray absorptiometry (SXA). 578 men and 702 women born in Norway in the age-groups 40/45, 60 and 75 years were included in the analyses. Socioeconomic regions, based on a social index dividing Oslo in two regions - East and West, were used. RESULTS: Age-adjusted mean BMD in women living in the less affluent Eastern region was 0.405 g/cm2 and significantly lower than in West where BMD was 0.419 g/cm2. Similarly, the odds ratio of low BMD (Z-score
PubMed ID
18036226 View in PubMed
Less detail

Prescription of anti-osteoporosis drugs during 2004-2007-a nationwide register study in Norway.

https://arctichealth.org/en/permalink/ahliterature94819
Source
Eur J Clin Pharmacol. 2009 Nov 7;
Publication Type
Article
Date
Nov-7-2009
Author
DevoldHelene
DoungGia
TverdalAage
FuruKari
MeyerHaakon
FalchJan
SogaardAnne
Author Affiliation
Department of Chronic Diseases, Norwegian Institute of Public Health, P.b. 4404 Nydalen, 0403, Oslo, Norway, helene.devold@fhi.no.
Source
Eur J Clin Pharmacol. 2009 Nov 7;
Date
Nov-7-2009
Language
English
Publication Type
Article
Abstract
PURPOSE: To assess 1-year prevalence, incidence rates and minimum refill of anti-osteoporosis drug use in Norway by age, gender and place of residence during 2004-2007. METHODS: Data from patients aged >/= 40 years receiving anti-osteoporosis drugs (AOD) were retrieved from the Norwegian Prescription Database (NorPD). AOD were defined as bisphosphonates (alendronate with or without cholecalciferol, risedronate, ibandronate and etidronate with or without calcium), raloxifene, teriparatide and nasal calcitonin. The NorPD covers the total Norwegian population in ambulatory care. Key measurements were 1-year prevalence, incidence rate and minimum refill. RESULTS: Among Norwegian women and men >/= 40 years, 4.3 and 0.45% respectively used AOD in 2004. In 2007, the prevalence of AOD use had slightly increased to 4.6% in women and to 0.52% in men. In 2007, 90% of users were women. The use of alendronate, representing 88% of all AOD use in 2007, increased from 2004 to 2007 while the use of other bisphosphonates decreased. The counties with highest overall bisphosphonate use were the counties with the historically lowest incidence of osteoporotic fractures. The incidence rate of overall bisphosphonate use decreased from 2005 to 2007. Among those patients who were dispensed a bisphosphonate in 2005, 72% refilled at least one prescription both in 2006 and 2007. CONCLUSION: There was an increasing prevalence and a decreasing incidence of AOD use over this limited time period. There was substantial geographical variation in the prevalence of anti-osteoporosis drugs. We also observed a high minimum refill rate.
PubMed ID
19898839 View in PubMed
Less detail